Pfizer Receives CHMP Backing On EU Bevacizumab And Withdraws Skinny Label Adalimumab UPDATED
Pfizer was at the forefront of the CHMP’s December 2018 meeting concerning biosimilars, while Dipharma and PARI Pharma were backed on a generic and hybrid medicine apiece.
You may also be interested in...
Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.
Pfizer’s Amsparity biosimilar adalimumab has been endorsed by the EMA’s CHMP as a rival to Humira. At the same time, Accord has received positive opinions for generic azacitidine and dexmedetomidine.
Pfizer has received a pan-European marketing authorization for its Zirabev biosimilar bevacizumab, a rival to Genentech’s Avastin. The nod marks Pfizer’s second European approval for an oncology biosimilar.